Delivery of compounds for the treatment of Parkinsons through an inhalation route
First Claim
1. A condensation aerosol for delivery of a drug selected from the group consisting of benzotropine, pergolide, amantadine, deprenyl and ropinerole, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of antiparkinsons drugs through an inhalation route. In a method aspect of the present invention, an antiparkinsons drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiparkinsons drug on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering an antiparkinsons drug through an inhalation route is provided which comprises: a) a thin coating of a an antiparkinsons drug composition; and, b) a device for dispending said thin coating as a condensation aerosol.
-
Citations
40 Claims
- 1. A condensation aerosol for delivery of a drug selected from the group consisting of benzotropine, pergolide, amantadine, deprenyl and ropinerole, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
-
5. A method of producing a drug selected from the group consisting of benzotropine, pergolide, amantadine, deprenyl and ropinerole in an aerosol form comprising:
-
a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns. - View Dependent Claims (6, 7, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
-
36. A method of producing benzotropine in an aerosol form comprising:
-
a. heating a thin layer containing benzotropine, on a solid support, to produce a vapor of benzotropine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% benzotropine degradation products by weight, and an MMAD of about 0.2 and about 3 microns.
-
-
37. A method of producing pergolide in an aerosol form comprising:
-
a. heating a thin layer containing pergolide, on a solid support, to produce a vapor of pergolide, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% pergolide degradation products by weightm and an MMAD of about 0.2 and about 3 microns.
-
-
38. A method of producing amantadine in an aerosol form comprising:
-
a. heating a thin layer containing amantadine, on a solid support, to produce a vapor of amantadine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% amantadine degradation products by weight, and an MMAD of about 0.2 and about 3 microns.
-
-
39. A method of producing deprenyl in an aerosol form comprising:
-
a. heating a thin layer containing deprenyl, on a solid support, to produce a vapor of deprenyl, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% deprenyl degradation products by weight, and an MMAD of about 0.2 and about 3 microns.
-
-
40. A method of producing ropinerole in an aerosol form comprising:
-
a. heating a thin layer containing ropinerole, on a solid support, to produce a vapor of ropinerole, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% ropinerole degradation products by weight, and an MMAD of about 0.2 and about 3 microns.
-
Specification